Main content

    MMC Available Clinical Trials

    Breadcrumbs Navigation: Cancer Services > Treatment > Clinical Trials at MMC > You are here: MMC Available Trials

     


    Note: As of February 2016


    BRAIN:

    RTOG 1205
    Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma.

    Back to top


    BREAST:

    A011203
    A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer

    NRG-BR003
    A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node Negative Triple-Negative Invasive Breast Cancer.

    NSABP B-51 / RTOG 1304
    A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy.

    NSABP B-55
    A Randomized, Double-blind, Parallel group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

    RTOG 1119
    Phase II Randomized Study of Whole Brain Radiotherapy in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer.

    SWOG 1207 / NSABP B-53
    Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer (Breast Cancer Study – evaluating everolimus with endocrine therapy).

    Back to top


    GASTROINTESTINAL:

    RTOG 0848
    A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.

    E2211
    Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

    S1406
    Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer

    Back to top


    GENITOURINARY:

    RTOG 0815
    A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer.

    RTOG 0924
    Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial.

    SWOG S0931
    EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

    S1216
    A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer.

    Back to top


    GYNECOLOGIC

    GOG-0225
    Diet and Physical Activity Change or Usual Care in Improving Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

    GOG-0238
    A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterus Corpus.

    GOG-0263
    A Randomized Phase III Clinical Trial of Adjuvant Radiation vs. Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy.

    Back to top


    HEAD & NECK:

    NRG-HN001
    Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA).

    NRG-HN002
    A Randomized Phase II Trial For Patients with p16 Positive, Non-Smoking Associated, Lococregionally Advanced Oropharyngeal Cancer.

    RTOG 0920
    A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer.

    RTOG 1216
    Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Cetuximab and Docetaxel for High-Risk Squamous Cell Cancer of the Head and Neck.

    Back to top


    LEUKEMIA:

    E1912
    A Randomized Phase III Study of Ibrutinib-based Therapy vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL).

    Back to top


    LUNG:

    Alliance A081105
    Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC).

    Alliance A151216
    Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST).

    E4512
    A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer; Crizotinib vs. Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein.

    S1403
    A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naïve Patients with Advanced (Stage IV or recurrent), EGFR Mutation Positive Non-Small Cell Lung Cancer

    Back to top


    LYMPHOMA:

    E1412
    Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma.

    Back to top


    MISCELLANEOUS:

    Music Therapy
    Effects of Music Therapy Interventions on Pain Perception of Cancer Patients (in hospital only)

    Back to top


    Myeloma

    E3A06
    Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma.

    Back to top

    Contacts

    For additional information regarding the above Clinical Trials,
    please contact one of our Cancer Research Coordinators:

    Elise Fredeking, RN, BSN, OCN
    209-526-4500, ext. 6192

    Denise Galbawy, RN, BSN, OCN, CCRC
    209-572-7116.